# A Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Participants With Moderate to Severe Atopic Dermatitis

> **NCT07754786** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 520 (estimated)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Dupilumab Injection
- **DRUG:** IBI3027

## Key facts

- **NCT ID:** NCT07754786
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-20
- **Primary completion:** 2028-07-01
- **Final completion:** 2028-08-26
- **Target enrollment:** 520 (ESTIMATED)
- **Last updated:** 2026-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07754786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07754786, "A Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Participants With Moderate to Severe Atopic Dermatitis". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07754786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*